MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1007/s10157-018-1635-6

Медицинская библиотека · Clinical and experimental nephrology · 2018

Pharmacodynamics of evocalcet for secondary hyperparathyroidism in Japanese hemodialysis patients.

Shigematsu Takashi, Shimazaki Ryutaro, Fukagawa Masafumi, Akizawa Tadao, Evocalcet Study Group

Клиническое исследование I фазыКлиническое исследование II фазыСтатьяМногоцентровое исследованиеПеревод в очереди

Аннотация

BACKGROUND

This study investigated the pharmacokinetics, pharmacodynamics, and safety of multiple doses of evocalcet in Japanese secondary hyperparathyroidism (SHPT) patients receiving hemodialysis.

METHODS

In this multicenter, open-label study, conducted between August 2013 and March 2014, 27 patients received multiple doses of 1 and 4 mg evocalcet for 14 days, followed by an extension period of multiple doses of 8 and 12 mg evocalcet for 7 days using an intra-patient dose escalation protocol. Pharmacodynamic parameters consisted of measurement of intact parathyroid hormone (PTH), serum-corrected calcium, serum phosphorus and intact fibroblast growth factor 23 concentrations. Safety was assessed by analysis of adverse events.

RESULTS

Plasma evocalcet levels reached steady state 3 days after the first day of administration. Pharmacodynamic analyses showed that evocalcet effectively reduced intact PTH and serum-corrected calcium levels. Adverse events (AEs) occurred in 29.6 and 62.5% of patients receiving multiple doses of 1 or 4 mg, respectively. The AE 'blood calcium decreased' occurred in eight patients (33.0%) after multiple doses of 4 mg. All events were mild, except for one patient with a moderate AE (abnormal liver function) and one patient with a severe adverse drug reaction (blood calcium decreased).

CONCLUSION

Multiple doses of evocalcet reduced intact PTH levels with a concomitant decrease in serum calcium levels. Evocalcet was well tolerated in SHPT patients receiving hemodialysis.

Для цитирования: Shigematsu Takashi, Shimazaki Ryutaro, Fukagawa Masafumi, Akizawa Tadao, Evocalcet Study Group. Pharmacodynamics of evocalcet for secondary hyperparathyroidism in Japanese hemodialysis patients.. Clinical and experimental nephrology. 2018. DOI: 10.1007/s10157-018-1635-6.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.